High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020–July 2021
PLOS ONE · 26.06.2024 · 19 (6) · e0305129
DOI: 10.1371/journal.pone.0305129 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 26.06.2024. Verfasst von Grace A Namayanja und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Global HIV and TB, US Centers for Disease Control and Prevention, Kampala, Uganda. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, HIV Infections, Oxazines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).
Abstract (Originalsprache)
Background
In 2019, WHO recommended dolutegravir (DTG) as a backbone for first- and second-line antiretroviral therapy (ART) regimens for people living with HIV (PLHIV). According to the 2018 Uganda’s HIV treatment guidelines, patients with viral non-suppression (≥1,000 copies/mL) should receive intensive adherence counseling (IAC) with repeat viral load (VL) within 6 months. This analysis focused on the prevalence and factors associated with viral suppression following IAC among PLHIV on DTG-based regimens (DBRs) with an initial episode of viral non-suppression (VNS) in Uganda.
Methods
We conducted a retrospective analysis for PLHIV on DBRs with an initial episode of VNS (≥1,000 copies/mL) in Uganda during October 2019–September 2020 who had a follow up VL test result during September 2020–July 2021. Data were abstracted from the Central Public Health Laboratory (CPHL) database, including patient demographics and VL results. Viral non-suppression (VNS) was defined as a VL test result of ≥1,000 copies/mL. We characterized PLHIV on DBRs and used logistic regression models to determine factors associated with VL suppression after an initial episode of VNS.
Results
A total of 564 PLHIV on DBRs with an initial episode of VNS were followed up and 43 were excluded due to missing data. Of the 521, 220 (42.2%) were children (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Global HIV and TB, US Centers for Disease Control and Prevention, Kampala, Uganda.
- Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
- Central Public Health Laboratories, Ministry of Health, Kampala, Uganda.
- Monitoring and Evaluation Technical Support, Makerere University School of Public Health, Kampala, Uganda.
- Office of Health and HIV, United States Agency for International Development, Kampala, Uganda.
- Walter Reed Army Institute of Research, US Mission, Kampala, Uganda.
ORCID-Profile: Grace A Namayanja, Estella Birabwa
Zitieren
APA
Namayanja, G. A., Da Silva, J. F., Elur, B., Nasirumbi, P. M., Raizes, E., Ssempiira, J., Nazziwa, E., Nabukenya, M., Sewanyana, I., Balaba, J., Ntale, J., Calnan, J., Birabwa, E., Akao, J., Mwangi, C., Naluguza, M., Ahimbisibwe, A., Katureebe, C., Nabadda, S., …, & Dirlikov, E. (2024). High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020–July 2021. PLOS ONE, 19(6), e0305129. https://doi.org/10.1371/journal.pone.0305129
Vancouver
Namayanja GA, Da Silva JF, Elur B, Nasirumbi PM, Raizes E, Ssempiira J, et al. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020–July 2021. PLOS ONE. 2024;19(6):e0305129. doi:10.1371/journal.pone.0305129
BibTeX
@article{Namayanja2024,
author = {Namayanja, Grace A and Da Silva, Juliana de Fatima and Elur, Bill and Nasirumbi, Pamela M and Raizes, Elliot and Ssempiira, Julius and Nazziwa, Esther and Nabukenya, Miriam and Sewanyana, Isaac and Balaba, Jennifer and Ntale, Jonathan and Calnan, Jackie and Birabwa, Estella and Akao, Juliet and Mwangi, Christina and Naluguza, Mary and Ahimbisibwe, Arthur and Katureebe, Cordelia and Nabadda, Susan and Nelson, Lisa and Dirlikov, Emilio},
title = {High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020–July 2021},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0305129},
doi = {10.1371/journal.pone.0305129}
}
EUVIMED